De-Risking the Discovery & Development of Safe & Effective Best-in-Class PROTACs, Molecular Glues & DACs

With the first anticipated PROTAC approval and multiple candidates advancing through clinical trials, 2026 was a pivotal year for the global targeted-protein degradation (TPD) industry. This global momentum is fueled Korea’s own TPD boom: over $144M raised in the past 12 months, alongside strategic collaborations from leaders like Ubix Therapeutics, Prazer Therapeutics, and Bridge Biotherapeutics.

The inaugural World TPD & Induced Proximity Summit South Korea was the only event dedicated to gathering the Asian biopharma focused on end-to-end TPD drug development. Featuring key international opinion leaders, deep dives into preclinical and clinical strategy, and expanded content on molecular glues and novel E3 ligases, this summit was your chance to de-risk your pipelines, learn from international experts, and build the global collaborations needed to advance best-in-class TPD therapeutics.

Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this was the opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.